Monoclonal Antibody Therapeutics Industry Poised for Rapid Expansion, Projected to Hit $354.11 Billion by 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Much Is the Global Monoclonal Antibody Therapeutics Market Valued at Present and by 2029?
In recent times, the monoclonal antibody therapeutics market has seen significant expansion. From $199.98 billion in 2024, it is predicted to see a rise to $224.62 billion in 2025, indicating a compound annual growth rate (CAGR) of 12.3%. The previously observed growth can be linked to the increasing incidence of chronic diseases, heightened need for targeted therapies, elevated usage in the field of oncology treatment, expanded biopharmaceutical production, government support for biologics study, and an upsurge in autoimmune illnesses.
Rapid expansion is projected for the monoclonal antibody therapeutics market in the upcoming years, with an anticipated worth of $354.11 billion by 2029, reflecting a compound annual growth rate (CAGR) of 12.1%. The escalation during the forecasted time can be ascribed to the advancement of personalized medicine, an upsurge in the aging population, extending applications for sanctioned mAbs, amplified healthcare expenditure, and heightened cognizance among medical professionals. The major trends expected within the forecasted period encompass the fabrication of bispecific antibodies, progress in hybridoma technology, application of AI in antibody discovery, improvements in glycoengineering, uninterrupted bioprocessing technologies, and application of gene editing tools for amplified expression.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25839&type=smp
#What Drivers Are Influencing Growth In The Monoclonal Antibody Therapeutics Market?
The growth of the monoclonal antibody therapeutics market is poised to be driven by the increasing incidence of autoimmune diseases. These diseases involve the immune system attack on the body’s own tissues and organs, mistakenly regarded as foreign threats, causing chronic inflammation and tissue damage. The higher occurrence of these conditions is due to changes in the environment, with heightened exposure to pollutants and modified microbial environments purportedly activating abnormal immune reactions in predisposed individuals. Monoclonal antibody therapies are particularly beneficial for autoimmune ailments as they precisely identify and obstruct certain immune routes responsible for inflammation and tissue damage, thus alleviating symptoms and slowing the progression of the disease. For instance, a report released in March 2023 by the Office for Health Improvement & Disparities, a UK government department, reported that in 2022, 17.6% of people aged 16 and above self-disclosed a long-term musculoskeletal (MSK) disorder, a condition triggered by autoimmune diseases, rising from 17.0% in 2021. Hence, the escalating incidence of autoimmune diseases is fueling the expansion of the monoclonal antibody therapeutics market.
What Are The Main Segments Identified In The Monoclonal Antibody Therapeutics Market Research?
The monoclonal antibody therapeutics market covered in this report is segmented –
1) By Product Type: Naked, Fusion Protein, Antibody Fragment, Conjugate, Multi-Specific
2) By Therapy Area: Autoimmune And Inflammatory Disorders, Oncology, Hematology, Ophthalmology, Other Therapy Areas
3) By Application: Cancer, Autoimmune Diseases, Infection, Hematological Diseases, Other Applications
4) By End User: Hospitals, Private Clinics, Research Institute
Subsegments:
1) By Naked: Fully Human Antibodies, Humanized Antibodies, Chimeric Antibodies
2) By Fusion Protein: Receptor Fusion Proteins, Ligand Fusion Proteins
3) By Antibody Fragment: Single-Chain Variable Fragment, Fab Fragments, Diabodies
4) By Conjugate: Antibody-Drug Conjugates, Radioimmunoconjugates, Immunotoxins
5) By Multi-Specific: Bispecific Antibodies, Trispecific Antibodies, T-Cell Engagers
What Upcoming Trends Are Expected To Impact The Monoclonal Antibody Therapeutics Market Globally?
Key players in the monoclonal antibody therapeutics market are striving to bring forth innovative solutions such as bispecific monoclonal antibodies. These solutions are aimed at boosting treatment efficiency by targeting two different antigens or epitopes at once. Bispecific monoclonal antibodies are a unique class of engineered antibodies that have the capability to bind to two distinct antigens or to two separate epitopes of the same antigen. For example, Roche Holding AG, a pharmaceutical firm based in Switzerland, introduced Vabysmo (faricimab-svoa) in March 2024. This bispecific monoclonal antibody is used for treating eye diseases, specifically neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema post retinal vein occlusion (RVO). It concentrates on VEGF-A and Angiopoietin-2 (Ang-2), resulting in enhanced vascular stability and decreased retinal fluid leakage. Its double-targeting mechanism paves the way for dosing intervals up to four months, considerably reducing the treatment burden for patients.
Which Companies Play A Key Role In The Development Of The Monoclonal Antibody Therapeutics Market?
Major companies operating in the monoclonal antibody therapeutics market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer Aktiengesellschaft, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Daiichi Sankyo Company Limited, UCB S.A., Genmab A/S, ADC Therapeutics, Arcus Biosciences, Y-mAbs Therapeutics
Get The Full Report Here:
What Are The Key Regional Developments Shaping The Monoclonal Antibody Therapeutics Market?
North America was the largest region in the monoclonal antibody therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the monoclonal antibody therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=25839&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
